Entera Bio logo
Entera Bio
ENTX | NASDAQ
Chart Builder DCF Calculator
$3.02
-$0.09 (-2.89%)
At close: Nov 16, 2026, 4:00 PM ET
$2.93
-$0.09 (-2.98%)
After-hours: Nov 16, 2026, 7:03 PM ET

Entera Bio Company Profile

Company profile explained

Company Profile

Entera Bio Ltd. is a biopharmaceutical firm in the clinical development phase, dedicated to creating and marketing oral medications composed of large molecules, addressing medical conditions that currently lack adequate treatments. Its primary experimental drugs are EB612, currently undergoing Phase II clinical assessment for hypoparathyroidism, and EB613, which has concluded Phase II studies for osteoporosis and is now in Phase I trials for treating non-healing bone fractures. Furthermore, the company holds a collaborative research and licensing pact with Amgen Inc. aimed at identifying and advancing potential therapeutic compounds for inflammatory conditions and other grave ailments. Established in 2009, Entera Bio Ltd. operates from its headquarters in Jerusalem, Israel.

Key Executives

Name Position
Miranda J. Toledano Chief Executive Officer & Director
Dana Yaacov-Garbeli Chief Financial Officer
Hillel Galitzer Chief Operating Officer
Cherin Smith Executive Vice President & Head of Clinical Operations
Constantin Itin Head of Biopharmaceutics & Bioanalytics
Gregory Burshtein Chief of Research & Development
Michele McDermott MD & EVP of Medical Affairs
Rachel Wagman Chief Clinical Advisor
Riccardo Paolo Camisasca Chief Medical Officer

Latest SEC Filings

Date Type Title
Oct 30, 2026 SC 13G Statement of acquisition of beneficial ownership b...
Oct 27, 2026 8-K Current Report
Oct 14, 2026 DEF 14A Filing
Oct 06, 2026 8-K Current Report
Sep 23, 2026 PRE 14A Filing
Aug 28, 2026 EFFECT Filing
Aug 28, 2026 424B3 Filing
Aug 21, 2026 S-3 Filing
Aug 21, 2026 3 Filing
Aug 18, 2026 8-K Current Report
View All SEC Filings ➞
Entera Bio
Entera Bio logo
Country Israel
IPO Date Jun 28, 2018
Industry Biotechnology
Sector Healthcare
Employees 21
CEO Miranda J. Toledano

Contact Details

Kiryat Hadassah Minrav Building Jerusalem, JM 9112002 Israel

Stock Details

Ticker Symbol ENTX
Exchange NASDAQ
Fiscal Year January - December
Reporting Currency USD
CIK Code 0001638097
CUSIP Number M40527109
ISIN Number IL0011429839
SIC Code 2836

© 2026 bestshares.com. All rights reserved.

All data is for informational purposes only. bestshares.com is not a broker, dealer, or registered investment adviser, and nothing on this site is a recommendation to buy or sell any security.